| Protocol ID |
|
Title |
|
| RTOG 0534 |
|
A Phase III Trial of Short Term Androgen Deprivation with Pelvic Lymph Node or Prostate Bed Only Radiotherapy (SPPORT) in Prostate Cancer Patients with a Rising PSA After Radical Prostatectomy
Keywords: Prostate Cancer Patients with a Rising PSA After Radical Prostatectomy |
|
| In-House |
|
Management of Intra-Fractional Prostate Motion During Radiation Therapy
Keywords: radiation therapy |
|
| RTOG 0621 |
|
Adjuvant 3DCRT/IMRT in Combination with Andgrogen Suppression and Docetaxel for High Risk Prostate Cancer Patients Post- Prostatectomy: A Phase II Trial
Keywords: High Risk Prostate Cancer Patients Post- Prostatectomy |
|
| RTOG 0524 |
|
Phase I/II Trial of a Combination of Paclitaxel alone with Daily Irradiation Following Transurethral Surgery for Non-Cystectomy Candidates with Muscle-Invasive Bladder Cancer
Keywords: after transurethral surgery for non-cystectomy patients with muscle invasive bladder cancer |
|
| In-House |
|
Phase I/II Trial Examining Dose-Per-Fraction Escalation Using Intensity Modulated Radiation Therapy in the Treatment of Prostate Cancer
Keywords: prostate cancer |
|
| U of C 14954A |
|
A Randomized, Phase II Study of GW786034 (Pazopanib) in Stage D0 Relapsed Androgen Sensitive Prostate Cancer Following Limited GnRH Agonist Therapy
Keywords: Stage D0 Relapsed Androgen Sensitive Prostate Cancer |
|
| A6181120 |
|
A Multicenter, Randomized, Double-Blind, Phase III Study of Sunitinib plus Prednisone v. Prednisone in Patients with Progressive Metatstatic Hormone-Refractory Prostate Cancer after Failure of a Docetaxel-Based Chemotherapy Regimen
Keywords: Patients with Progressive Metatstatic Hormone-Refractory Prostate Cancer |
|
| E2804 |
|
A Randomized Phase II Study of VEGF, RAF Kinase, and mTOR Combination Targeted Therapy (CTT) with Bevacizumab, Sorafenib and Temsirolimus in Advanced Renal Cell Carcinoma
Keywords: advanced renal cell canrcinoma |
|
| In-House |
|
Safety of Biclutamide in chemoprevention of transitional cell carcinoma of the bladder treated with BCG
Keywords: transitional cell carcinoma of the bladder treated with BCG |
|
| In-House |
|
Urinary HMGB1 in Subjects with Urologic Diseases
Keywords: urologic diseases |
|
| Industry 15 |
|
A Phase III, Randomized, Placebo-Controlled, Double-Blind Study to Assess the Efficacy and Safety of Once-daily Orally Administered ZD4054 10 mg in Non-Metastatic Hormone-Resistant Prostate Cancer Patients
Keywords: non-metastatic hormone-resistant prostate cancer patients |
|
| Industry 14 |
|
A Phase III, Randomised, Double-blind Study to Assess the Efficacy and Safety of 10 mg ZD4054 versus Placebo in Patients with Hormone-resistant Prostate Cancer and Bone Metastasis who are Pain Free or Mildly Symptomatic.
Keywords: Patients with Hormone-resistant Prostate Cancer and Bone Metastasis who are Pain Free or Mildly Symptomatic |
|
| Industry 33 |
|
A Phase III, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of 10 mg ZD4054 in Combination with Docetaxel in comparison with Docetaxel in Patients with Metastatic Hormone-Resistant Prostate Cancer
Keywords: patients with metastatic hormone-resistant prostate cancer |
|
| HIFU |
|
Investigational Plan EDAP Ablatherm Integrated Imaging High Intensity Focused Ultrasound (HIFU) Indicated for Treatment of Low Risk, Localized Prostate Cancer
Keywords: localized prostate cancer |
|
| Industry |
|
A Randomized Double-Blind Parallel Group Study Comparing Casodex 50mg plus Placebo to Casodex 50mg plus dutasteride 3.5mg Administered for 18 months to Men with Prostate Cancer Who Have Failed First-Line Androgen Deprivation Therapy (Assessed by Rising PSA) Followed by a Two-Year Extension Phase AVO108943
Keywords: Men with Prostate Cancer Who Have Failed First-Line Androgen Deprivation Therapy (Assessed by Rising PSA) |
|
| In-House |
|
MicroRNA Distribution along Human Nephrons Bank.
Keywords: |
|
| S0421 |
|
Phase III Study of Docetaxel and Atrasentan vs. Docetaxel and Placebo for Patients with Advanced Hormone Refractory Prostate Cancer
Keywords: Advanced Hormone Refractory Prostate Cancer |
|
| RTOG 0873/ NCIC CTG PR.11 |
|
A Phase III Study of Active Surveillance Therapy Against Radical Treatment in Patients Diagnosed with Favourable Risk Prostate Cancer (START)
Keywords: Favourable Risk Prostate Cancer |
|
| E3805 |
|
CHAARTED: ChemoHormonal Therapy v. Androgen Ablation Randomized Trial for Extensive Disease in Prostate Cancer
Keywords: Extensive Disease in Prostate Cancer |
|
| U of C 15393B |
|
A Randomized, Double-Blind, Placebo-Controlled Phase II Study of Testosterone Replacement in Men with Non-Metastatic Castrate Resistant Prostate Cancer
Keywords: Non-Metastatic Castrate Resistant Prostate Cancer |
|
| In-House: Frailty & Mobility Disorder |
|
Development of Frailty and Mobility Disorders in Older Prostate Cancer Patients on Androgen Deprivation Therapy
Keywords: Older Prostate Cancer Patients on Androgen Deprivation Therapy |
|
| EFC6668 |
|
Randomized Study of Larotaxel + Cisplatin (LC) vs. Gemcitabine + Cisplatin (GC) in the First Line Treatment of Locally Advanced/ Metastatic Urothelial Tract or Bladder Cancer
Keywords: First Line Treatment of Locally Advanced/ Metastatic Urothelial Tract or Bladder Cancer |
|
| Univ. of Michigan 2005.145 |
|
Randomized Blinded Phase II Trial of Maintenance SU011248 vs. Placebo Post Chemotherapy for Patients with Advanced Urothelial Carcinoma
Keywords: Advanced Urothelial Carcinoma |